

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Cryofocus Medtech (Shanghai) Co., Ltd.**

**康豐生物科技(上海)股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6922)**

## **ANNOUNCEMENT IN RELATION TO GRANT OF LISTING APPROVAL BY STOCK EXCHANGE FOR IMPLEMENTATION OF H SHARE FULL CIRCULATION**

Reference is made to the announcement of Cryofocus Medtech (Shanghai) Co., Ltd. (康豐生物科技(上海)股份有限公司) (the “**Company**”) dated March 11, 2024 in relation to the issuance of the Filing Notice by the CSRC in respect of the CSRC Filing (the “**Announcement**”). Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

### **LISTING APPROVAL BY THE STOCK EXCHANGE**

The Company has applied to the Listing Committee of the Stock Exchange for the approval (the “**Listing Approval**”) of the listing of, and the permission to deal in, 29,341,981 H shares of the Company (“**Converted H Shares**”), representing the maximum number of unlisted shares of the Company (“**Unlisted Shares**”) to be converted under the Conversion and Listing. The Company is pleased to announce that the Listing Approval was granted by the Stock Exchange on April 3, 2024, subject to fulfillment of all other conditions of the Conversion and Listing.

### **SHAREHOLDING STRUCTURE**

The Conversion and Listing will involve an aggregate of 29,341,981 Unlisted Shares held by eight participating shareholders (the “**Participating Shareholders**”). Below sets out the respective shareholding percentage in the Company of the Participating Shareholders upon completion of the Conversion and Listing.

Name of the Participating Shareholders	Number of Unlisted Shares to be converted to H shares of the Company (“H Shares”)	Approximate percentage of total issued shares of the Company upon completion of the Conversion and Listing
LV Shiwen (呂世文)	10,934,994	4.57%
Galaxy Yuanhui Investment Co., Ltd.* (銀河源匯投資有限公司)	3,839,976	1.61%
Qingdao Marine Innovation Industry Investment Fund Co., Ltd.* (青島海洋創新產業投資基金有限公司)	2,844,072	1.19%
Zhuhai Junheng Investment L.P. (Limited Partnership)* (珠海鈞恒投資合夥企業(有限合夥))	3,867,792	1.62%
TD Engineering	3,323,191	1.39%
SHEN Yao (申堯)	2,515,775	1.05%
Suzhou Proxima Venture Investment L.P. (Limited Partnership)* (蘇州比鄰星創業投資合夥企業(有限合夥))	1,512,962	0.63%
XU Li (徐力)	503,219	0.21%
<b>Total</b>	<b>29,341,981</b>	<b>12.27%</b>

\* For identification purposes only

Upon completion of the Conversion and Listing, the share capital structure of the Company will be as follows:

Description of shares	As at the date of this announcement		Upon completion of the Conversion and Listing	
	<i>Number of shares</i>	<i>Approximate percentage</i>	<i>Number of shares</i>	<i>Approximate percentage</i>
H Shares	114,096,598	47.72%	143,438,579	59.99%
Unlisted Shares	125,013,402	52.28%	95,671,421	40.01%
<b>Total</b>	<b>239,110,000</b>	<b>100.00%</b>	<b>239,110,000</b>	<b>100.00%</b>

The Company shall complete the relevant conversion and trading procedures in respect of the Converted H Shares and will make further announcement(s) on the progress of the Conversion and Listing in compliance with the requirements under applicable laws and regulations (including the Listing Rules) as and when appropriate.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Cryofocus Medtech (Shanghai) Co., Ltd.**  
**Mr. LI Kejian**  
*Chairman of the Board*

Hong Kong, April 3, 2024

*As at the date of this announcement, the Board comprises Mr. LI Kejian, Mr. ZHU Jun and Mr. LIU Wei as executive Directors, Mr. LV Shiwen and Mr. ZHAO Chunsheng as non-executive Directors, and Dr. GAO Dayong, Mr. LIANG Hsien Tse Joseph, Dr. QIN Zheng and Dr. HU Henan as independent non-executive Directors.*